Freemen Nutra Group, a global ingredient supplier, has announced a new partnership with RAWGA Inc., an ingredient development company from South Korea focused on sustainability. Together, the companies will introduce VC-H1, a novel plant-based collagen peptide, to the North American market.
Hibiscus Collagen Peptide Outperforms Animal Peptides
VC-H1 (INCI: Not Provided) is sourced from organically grown hibiscus and is composed of bioactive peptides from a collagen-like protein, along with free-radical scavenging hibiscus polyphenols.
According to clinical research published in the International Journal of Molecular Sciences, VC-H1 stimulates collagen production more effectively than traditional animal-sourced collagen peptides and provides multiple validated skin health benefits at a 1.5 g dose.
The randomized, double-blind, placebo-controlled clinical study demonstrated that VC-H1 provided significant benefits including:
- Deep, lasting hydration,
- Improved bounce and firmness,
- Enhanced skin surface texture and
- Visible age-defying effects.
“The key to the efficacy of VC-H1, and any collagen really, are the short two- to four-amino-acid-length peptides that stimulate collagen production in the body,” noted Eric Withee, director of innovation at Freemen Nutra. “And VC-H1 has a very low molecular weight, meaning it is made almost entirely of these collagen-boosting peptides.”
Science-backed Solution in High-demand Category
"We see this as a tremendous opportunity to bring to our customers, especially those with a focus on sustainability, a research-backed ingredient in a high-demand category," commented Hanks Li, president of Freemen Nutra.
"VC-H1 is not only an innovative option within the collagen market, but with a 1.5 g dose, many if not most of our customers will also see a cost savings. That is truly a rare opportunity."
